Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash.
Morrow Sodali is serving as the proxy solicitor for Patheon N.V.
Related News
Shareholder activism: the reality of an escalating threat in Spain
08 June 2025
Sodali & Co improves ranking across the board as UK Financial PR adviser to FTSE companies
03 June 2025
Hayden Mattiske Joins Judging Panel for the 75th Australasian Reporting Awards
05 May 2025
CSRD and Omnibus: Implications of Recent Changes on Corporate Disclosure
24 April 2025
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right